Clinical Trial Update: A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update of bevacizumab (Avastin) in women with HER2-negative metastatic breast cancer; the study has completed and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-01-27